{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:19:58Z","timestamp":1791321598708,"version":"4.3.1"},"reference-count":193,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004385","name":"Ghent University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek Vlaanderen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.pharmthera.2022.108161","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T11:04:08Z","timestamp":1645095848000},"page":"108161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["In vitro functional assays as a tool to study new synthetic opioids at the \u03bc-opioid receptor: Potential, pitfalls and progress"],"prefix":"10.1016","volume":"235","author":[{"given":"Marthe M.","family":"Vandeputte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Vasudevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe P.","family":"Stove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2022.108161_bb0005","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00414-021-02729-2","article-title":"Blood concentrations of new synthetic opioids","volume":"136","author":"Adamowicz","year":"2021","journal-title":"International Journal of Legal Medicine"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0010","article-title":"Molecular mechanisms of opioid receptor-dependent signaling and behavior","volume":"1","author":"Al-Hasani","year":"2011","journal-title":"Anesthesiology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2020.110553","article-title":"In vitro characterization of new psychoactive substances at the \u03bc-opioid, CB1, 5HT1A, and 5-HT2A receptors\u2014On-target receptor potency and efficacy, and off-target effects","volume":"317","author":"\u00c5strand","year":"2020","journal-title":"Forensic Science International"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0020","article-title":"Activation of the \u03bc-opioid receptor by alicyclic fentanyls: Changes from high potency full agonists to low potency partial agonists with increasing alicyclic substructure","volume":"dta.2906","author":"\u00c5strand","year":"2020","journal-title":"Drug Testing and Analysis"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0025","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2164-12-14","article-title":"Expression of G protein-coupled receptors and related proteins in HEK293, AtT20, BV2, and N18 cell lines as revealed by microarray analysis","volume":"12","author":"Atwood","year":"2011","journal-title":"BMC Genomics"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0030","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/02791072.1981.10471455","article-title":"The bogus drug: three methyl & alpha methyl fentanyl sold as \u201cChina White.\u201d","volume":"13","author":"Ayres","year":"1981","journal-title":"Journal of Psychoactive Drugs"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0035","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.3390\/molecules25173870","article-title":"Biased versus partial agonism in the search for safer opioid analgesics","volume":"25","author":"Azevedo Neto","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0040","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.62552","article-title":"\u00df2-Arrestin germline knockout does not attenuate opioid respiratory depression","volume":"10","author":"Bachmutsky","year":"2021","journal-title":"eLife"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/S2215-0366(19)30218-4","article-title":"Control of fentanyl-related substances in China","volume":"6","author":"Bao","year":"2019","journal-title":"The Lancet Psychiatry"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0050","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1111\/bph.15064","article-title":"Activation of \u03bc opioid receptors by MT-45 and its fluorinated derivatives","volume":"178","author":"Baptista-Hon","year":"2020","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0055","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.neuropharm.2017.08.016","article-title":"Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace","volume":"134","author":"Baumann","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0060","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1038\/s41467-019-11875-6","article-title":"Exploring use of unsupervised clustering to associate signaling profiles of GPCR ligands to clinical response","volume":"10","author":"Benredjem","year":"2019","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0065","doi-asserted-by":"crossref","first-page":"6179","DOI":"10.1074\/jbc.M109.085944","article-title":"G\u03b1i and G\u03b2\u03b3 jointly regulate the conformations of a G\u03b2\u03b3 effector, the neuronal G protein-activated K+ channel (GIRK)","volume":"285","author":"Berlin","year":"2010","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0070","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1038\/s41467-021-23736-2","article-title":"Site selective CH functionalization of mitragyna alkaloids reveals a molecular switch for tuning opioid receptor signaling efficacy","volume":"12","author":"Bhowmik","year":"2021","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0075","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1098\/rspb.1983.0093","article-title":"Operational models of pharmacological agonism","volume":"220","author":"Black","year":"1983","journal-title":"Proceedings of the Royal Society of London - Biological Sciences"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0080","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/dta.2738","article-title":"Report on a novel emerging class of highly potent benzimidazole NPS opioids: Chemical and in vitro functional characterization of isotonitazene","volume":"12","author":"Blanckaert","year":"2020","journal-title":"Drug Testing and Analysis"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0085","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1126\/science.286.5449.2495","article-title":"Enhanced morphine analgesia in mice lacking B-arrestin 2","volume":"286","author":"Bohn","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0090","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/35047086","article-title":"\u03bc-Opioid receptor desensitization by \u03b2-arrestin-2 determines morphine tolerance but not dependence","volume":"408","author":"Bohn","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0095","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0022-3565(24)37503-2","article-title":"Fentanyl and its analogs desensitize the cloned mu opioid receptor","volume":"285","author":"Bot","year":"1998","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0100","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1016\/j.bmc.2014.02.015","article-title":"Endomorphin analogues with mixed \u03bc-opioid (MOP) receptor agonism\/\u03b4-opioid (DOP) receptor antagonism and lacking \u03b2-arrestin2 recruitment activity","volume":"22","author":"Cai","year":"2014","journal-title":"Bioorganic & Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0105","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3389\/fphar.2018.00486","article-title":"Activity-based detection and bioanalytical confirmation of a fatal carfentanil intoxication","volume":"9","author":"Cannaert","year":"2018","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0110","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/jat\/bkaa066","article-title":"Report on a new opioid NPS: chemical and in vitro functional characterization of a structural isomer of the MT-45 derivative diphenpipenol","volume":"45","author":"Cannaert","year":"2020","journal-title":"Journal of Analytical Toxicology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0115","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1373\/clinchem.2018.289496","article-title":"Activity-based concept to screen biological matrices for opiates and (synthetic) opioids","volume":"64","author":"Cannaert","year":"2018","journal-title":"Clinical Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0120","doi-asserted-by":"crossref","first-page":"13873","DOI":"10.1021\/acs.jmedchem.1c01273","article-title":"A novel mitragynine analog with low efficacy mu-opioid receptor agonism displays antinociception with attenuated adverse effects","volume":"64","author":"Chakraborty","year":"2021","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0125","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.neuropharm.2013.08.028","article-title":"15 years of genetic approaches in vivo for addiction research: Opioid receptor and peptide gene knockout in mouse models of drug abuse","volume":"76","author":"Charbogne","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0130","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/j.1476-5381.2010.00863.x","article-title":"Elusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assays: Hemi-equilibrium in calcium assays","volume":"161","author":"Charlton","year":"2010","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0135","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/0024-3205(86)90090-1","article-title":"Evidence for coupling of the \u03ba opioid receptor to brain GTPase","volume":"39","author":"Clark","year":"1986","journal-title":"Life Sciences"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0140","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neubiorev.2018.12.005","article-title":"Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment","volume":"106","author":"Comer","year":"2019","journal-title":"Neuroscience & Biobehavioral Reviews"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0145","doi-asserted-by":"crossref","first-page":"586","DOI":"10.3390\/cells8060586","article-title":"Opioid-mediated astrocyte\u2013neuron signaling in the nucleus accumbens","volume":"8","author":"Corkrum","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0150","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0024-3205(92)90199-Y","article-title":"Opioid agonists binding and responses in SH-SY5Y cells","volume":"50","author":"Costa","year":"1992","journal-title":"Life Sciences"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0155","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1021\/acschemneuro.0c00191","article-title":"Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum : Design, Synthesis, and Evaluation of Analogues with Improved Potency and G-protein Activation Bias at the \u03bc-Opioid Receptor","volume":"11","author":"Crowley","year":"2020","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0160","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41583-018-0028-x","article-title":"Opioid receptors: drivers to addiction?","volume":"19","author":"Darcq","year":"2018","journal-title":"Nature Reviews Neuroscience"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0165","series-title":"21 CFR Part 1308. Correction of Code of Federal Regulations: Removal of temporary listing of benzylfentanyl and thenylfentanyl as controlled substances., Pub. L. No. 21 CFR Part 1308","author":"DEA","year":"2010"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0170","series-title":"21 CFR Part 1308. Schedules of Controlled Substances: Temporary Placement of Fentanyl-Related Substances in Schedule I., Federal Register Volume 83, Number 25 5188\u20135192","author":"DEA","year":"2018"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0175","series-title":"21 CFR Part 1310. Designation of benzylfentanyl and 4-anilinopiperidine, precursor chemicals used in the illicit manufacture of fentanyl, as List I chemicals., Pub. L. No. 21 CFR Part 1310","author":"DEA","year":"2020"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0180","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2174\/138161212799040466","article-title":"Probing heterotrimeric G protein activation: applications to biased ligands","volume":"18","author":"Denis","year":"2012","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0185","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1146\/annurev.physiol.69.022405.154749","article-title":"Beta-arrestins and cell signaling","volume":"69","author":"DeWire","year":"2007","journal-title":"Annual Review of Physiology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0190","series-title":"Furanyl Fentanyl. Background information and evaluation of \u201cThree Factor Analysis\u201d (factors 4, 5 and 6) for Temporary Scheduling","author":"Drug and Chemical Evaluation Section, Office of Diversion Control, DEA","year":"2016"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0195","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.isci.2019.03.011","article-title":"Biased signaling of the mu opioid receptor revealed in native neurons","volume":"14","author":"Ehrlich","year":"2019","journal-title":"iScience"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0200","series-title":"Cyclopropylfentanyl: report on the risk assessment of N-phenyl N-1-(2-phenylethyl)piperidin-4-ylcyclopropanecarboxamide in the framework of the Council Decision on new psychoactive substances","author":"EMCDDA","year":"2018"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0205","author":"EMCDDA","year":"2018"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0210","series-title":"New psychoactive substances: global markets, glocal threats and the COVID 19 pandemic: an update from the EU early warning system","author":"EMCDDA","year":"2020"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0215","series-title":"European drug report 2020: trends and developments","author":"EMCDDA","year":"2020"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0220","series-title":"European drug report 2021: trends and developments","author":"EMCDDA","year":"2021"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0225","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0022-3565(25)20761-3","article-title":"Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor","volume":"278","author":"Emmerson","year":"1996","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114293","article-title":"Affinity, potency, efficacy, selectivity, and molecular modeling of substituted fentanyls at opioid receptors","volume":"182","author":"Eshleman","year":"2020","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0235","series-title":"In vitro screening of opioid antagonist effectiveness","author":"Feasel","year":"2018"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0240","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3390\/brainsci8090170","article-title":"Novel synthetic opioids: the pathologist\u2019s point of view","volume":"8","author":"Frisoni","year":"2018","journal-title":"Brain Sciences"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0245","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s00204-020-02726-1","article-title":"Toxicokinetics and toxicodynamics of the fentanyl homologs cyclopropanoyl-1-benzyl-4\u2032-fluoro-4-anilinopiperidine and furanoyl-1-benzyl-4-anilinopiperidine","volume":"94","author":"Gampfer","year":"2020","journal-title":"Archives of Toxicology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0250","doi-asserted-by":"crossref","first-page":"e411","DOI":"10.1038\/tp.2014.30","article-title":"The atypical antidepressant and neurorestorative agent tianeptine is a \u03bc-opioid receptor agonist","volume":"4","author":"Gassaway","year":"2014","journal-title":"Translational Psychiatry"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2210-3-1","article-title":"Activity of opioid ligands in cells expressing cloned mu opioid receptors","volume":"3","author":"Gharagozlou","year":"2003","journal-title":"BMC Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0260","doi-asserted-by":"crossref","first-page":"eaaz3140","DOI":"10.1126\/scisignal.aaz3140","article-title":"Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists","volume":"13","author":"Gillis","year":"2020","journal-title":"Science Signaling"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0265","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.tips.2020.09.009","article-title":"Critical assessment of G protein-biased agonism at the \u03bc-opioid receptor","volume":"41","author":"Gillis","year":"2020","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0270","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1124\/mol.119.119214","article-title":"Intrinsic efficacy of opioid ligands and its importance for apparent bias, operational analysis, and therapeutic window","volume":"98","author":"Gillis","year":"2020","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0275","doi-asserted-by":"crossref","DOI":"10.1007\/s12079-020-00590-3","article-title":"Opioid receptors signaling network","author":"Gopalakrishnan","year":"2021","journal-title":"Journal of Cell Communication and Signaling."},{"key":"10.1016\/j.pharmthera.2022.108161_bb0280","first-page":"697","article-title":"New and emerging illicit psychoactive substances","volume":"102","author":"Graddy","year":"2018","journal-title":"Medical Clinics"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2021.110989","article-title":"Pharmacological and metabolic characterization of the novel synthetic opioid brorphine and its detection in routine casework","volume":"327","author":"Grafinger","year":"2021","journal-title":"Forensic Science International"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0290","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.tibtech.2020.11.007","article-title":"Linker engineering in the context of synthetic protein switches and sensors","volume":"39","author":"Gr\u00e4we","year":"2021","journal-title":"Trends in Biotechnology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0295","first-page":"1","article-title":"A novel G protein-biased agonist at the \u03bc opioid receptor induces substantial receptor desensitisation through G protein-coupled receptor kinase","author":"Groom","year":"2020","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0300","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/BF02161117","article-title":"\u00dcber Benzimidazolderivate mit starker analgetischer Wirkung","volume":"13","author":"Gross","year":"1957","journal-title":"Experientia"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0305","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fnins.2017.00017","article-title":"A practical guide to approaching biased agonism at G protein coupled receptors","volume":"11","author":"Gundry","year":"2017","journal-title":"Frontiers in Neuroscience"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0310","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1111\/bph.14913","article-title":"G protein-biased kratom-alkaloids and synthetic carfentanil-amide opioids as potential treatments for alcohol use disorder","volume":"177","author":"Gutridge","year":"2020","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0315","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1002\/dta.2822","article-title":"In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis","volume":"12","author":"Hassanien","year":"2020","journal-title":"Drug Testing and Analysis"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0320","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1021\/acsmedchemlett.9b00404","article-title":"Synthesis and \u03bc-opioid activity of the primary metabolites of carfentanil","volume":"10","author":"Hsu","year":"2019","journal-title":"ACS Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0325","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.511","article-title":"Synthesis and pharmacological characterization of ethylenediamine synthetic opioids in human \u03bc-opiate receptor 1 (OPRM1) expressing cells","volume":"7","author":"Hsu","year":"2019","journal-title":"Pharmacology Research & Perspectives"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0330","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.97222","article-title":"Fentanyl-related designer drugs W-18 and W-15 lack appreciable opioid activity in vitro and in vivo","volume":"2","author":"Huang","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0335","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1097\/j.pain.0000000000001823","article-title":"Morphine produces potent antinociception, sedation, and hypothermia in humanized mice expressing human mu-opioid receptor splice variants","volume":"161","author":"Huang","year":"2020","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0340","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/BF02161116","article-title":"Synthese basisch substituierter, analgetisch wirksamer Benzimidazol-Derivate","volume":"13","author":"Hunger","year":"1957","journal-title":"Experientia"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0345","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/hlca.19600430412","article-title":"Benzimidazol-Derivate und verwandte Heterocyclen III. Synthese von 1-Aminoalkyl-2-benzyl-nitro-benzimidazolen","volume":"43","author":"Hunger","year":"1960","journal-title":"Helvetica Chimica Acta"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0350","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1373\/clinchem.2017.281626","article-title":"The fentanyl epidemic and evolution of fentanyl analogs in the United States and the European Union","volume":"65","author":"Jannetto","year":"2019","journal-title":"Clinical Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0355","series-title":"In Vitro Receptor and Transporter Assays for Abuse Liability Testing for the DEA by the VA","article-title":"Binding and functional activity at delta, kappa and mu opioid receptors: Acetyl fentanyl","author":"Janowsky","year":"2015"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0360","series-title":"In Vitro Receptor and Transporter Assays for Abuse Liability Testing for the DEA by the VA","article-title":"Binding and functional activity at delta, kappa and mu opioid receptors: Butyryl Fentanyl","author":"Janowsky","year":"2015"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0365","series-title":"In Vitro Receptor and Transporter Assays for Abuse Liability Testing for the DEA by the VA","article-title":"Binding and functional activity at delta, kappa and mu opioid receptors: AH-7921","author":"Janowsky","year":"2015"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0370","series-title":"In Vitro Receptor and Transporter Assays for Abuse Liability Testing for the DEA by the VA","article-title":"Binding and functional activity at delta, kappa and mu opioid receptors: MT-45","author":"Janowsky","year":"2015"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0375","series-title":"In Vitro Receptor and Transporter Assays for Abuse Liability Testing for the DEA by the VA","article-title":"Binding and functional activity at delta, kappa and mu opioid receptors: 3-furanylfentanyl","author":"Janowsky","year":"2016"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0380","series-title":"In Vitro Receptor and Transporter Assays for Abuse Liability Testing for the DEA by the VA","article-title":"Binding and functional activity at delta, kappa and mu opioid receptors: Acryl fentanyl","author":"Janowsky","year":"2016"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0385","series-title":"In Vitro Receptor and Transporter Assays for Abuse Liability Testing for the DEA by the VA","article-title":"Binding and functional activity at delta, kappa and mu opioid receptors: Valeryl Fentanyl","author":"Janowsky","year":"2016"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0390","series-title":"In Vitro Receptor and Transporter Assays for Abuse Liability Testing for the DEA by the VA","article-title":"Binding and functional activity at delta, kappa and mu opioid receptors: U-47700","author":"Janowsky","year":"2016"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0395","series-title":"In Vitro Receptor and Transporter Assays for Abuse Liability Testing for the DEA by the VA","article-title":"Binding and functional activity at delta, kappa and mu opioid receptors: Crotonyl Fentanyl","author":"Janowsky","year":"2017"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0400","series-title":"In Vitro Receptor and Transporter Assays for Abuse Liability Testing for the DEA by the VA","article-title":"Binding and functional activity at delta, kappa and mu opioid receptors: Cyclohexyl fentanyl","author":"Janowsky","year":"2017"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0405","series-title":"In Vitro Receptor and Transporter Assays for Abuse Liability Testing for the DEA by the VA","article-title":"Binding and functional activity at delta, kappa and mu opioid receptors: Cyclopentyl fentanyl","author":"Janowsky","year":"2017"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0410","series-title":"In Vitro Receptor and Transporter Assays for Abuse Liability Testing for the DEA by the VA","article-title":"Binding and functional activity at delta, kappa and mu opioid receptors: 3-Fluorofentanyl","author":"Janowsky","year":"2017"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0415","series-title":"In Vitro Receptor and Transporter Assays for Abuse Liability Testing for the DEA by the VA","article-title":"Binding and functional activity at delta, kappa and mu opioid receptors: Ocfentanil","author":"Janowsky","year":"2017"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0420","series-title":"In Vitro Receptor and Transporter Assays for Abuse Liability Testing for the DEA by the VA","article-title":"Binding and functional activity at delta, kappa and mu opioid receptors: Phenyl fentanyl","author":"Janowsky","year":"2017"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0425","series-title":"In Vitro Receptor and Transporter Assays for Abuse Liability Testing for the DEA by the VA","article-title":"Binding and functional activity at delta, kappa and mu opioid receptors: 4\u2032-methyl Fentanyl","author":"Janowsky","year":"2017"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0430","series-title":"In Vitro Receptor and Transporter Assays for Abuse Liability Testing for the DEA by the VA","article-title":"Binding and functional activity at delta, kappa and mu opioid receptors: Tetrahydrofuran fentanyl","author":"Janowsky","year":"2017"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0435","series-title":"In Vitro Receptor and Transporter Assays for Abuse Liability Testing for the DEA by the VA","article-title":"Binding and functional activity at delta, kappa and mu opioid receptors: U-47931E \/ Bromadoline","author":"Janowsky","year":"2017"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0440","series-title":"In Vitro Receptor and Transporter Assays for Abuse Liability Testing for the DEA by the VA","article-title":"Binding and functional activity at delta, kappa and mu opioid receptors: U-49900","author":"Janowsky","year":"2017"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0445","series-title":"In Vitro Receptor and Transporter Assays for Abuse Liability Testing for the DEA by the VA","article-title":"Binding and functional activity at delta, kappa and mu opioid receptors: ortho-methyl Acetyl Fentanyl","author":"Janowsky","year":"2018"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0450","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/104454900314672","article-title":"Kappa opioid receptor endocytosis by dynorphin peptides","volume":"19","author":"Jordan","year":"2000","journal-title":"DNA and Cell Biology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0455","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1113\/jphysiol.2014.283218","article-title":"Recruitment of G\u03b2\u03b3 controls the basal activity of G-protein coupled inwardly rectifying potassium (GIRK) channels: crucial role of distal C terminus of GIRK1","volume":"592","author":"Kahanovitch","year":"2014","journal-title":"The Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0460","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1248\/bpb.b20-00780","article-title":"Evaluation of agonistic activity of fluorinated and nonfluorinated fentanyl analogs on \u03bc-opioid receptor using a cell-based assay system","volume":"44","author":"Kanamori","year":"2021","journal-title":"Biological and Pharmaceutical Bulletin"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0465","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s11419-021-00602-w","article-title":"Agonistic activity of fentanyl analogs and their metabolites on opioid receptors","volume":"40","author":"Kanamori","year":"2021","journal-title":"Forensic Toxicology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0470","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1111\/bph.12222","article-title":"Efficacy and ligand bias at the \u03bc-opioid receptor: Efficacy and ligand bias at the \u03bc-opioid receptor","volume":"169","author":"Kelly","year":"2013","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0475","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/nrd2838","article-title":"Cellular assays as portals to seven-transmembrane receptor-based drug discovery","volume":"8","author":"Kenakin","year":"2009","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0480","doi-asserted-by":"crossref","first-page":"8895","DOI":"10.1021\/acs.jmedchem.8b01136","article-title":"Optimization of a series of mu opioid receptor (MOR) agonists with high G protein signaling bias","volume":"61","author":"Kennedy","year":"2018","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0485","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0165-6147(98)01279-6","article-title":"Opioids: first lessons from knockout mice","volume":"20","author":"Kieffer","year":"1999","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0490","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1111\/bph.15004","article-title":"Morphine-induced respiratory depression is independent of \u03b2-arrestin2 signalling","volume":"177","author":"Kliewer","year":"2020","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0495","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41467-018-08162-1","article-title":"Phosphorylation-deficient G-protein-biased \u03bc-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects","volume":"10","author":"Kliewer","year":"2019","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0500","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/1087057112461376","article-title":"A continuous, fluorescence-based assay of \u03bc-opioid receptor activation in AtT-20 cells","volume":"18","author":"Knapman","year":"2013","journal-title":"Journal of Biomolecular Screening"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0505","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1124\/mol.104.004994","article-title":"Receptor endocytosis counteracts the development of opioid tolerance","volume":"67","author":"Koch","year":"2005","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0510","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/1556-4029.14623","article-title":"Brorphine\u2014Investigation and quantitation of a new potent synthetic opioid in forensic toxicology casework using liquid chromatography-mass spectrometry","volume":"66","author":"Krotulski","year":"2020","journal-title":"Journal of Forensic Sciences"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0515","doi-asserted-by":"crossref","first-page":"6754","DOI":"10.1021\/jacs.6b00360","article-title":"Synthetic and receptor signaling explorations of the mitragyna alkaloids: mitragynine as an atypical molecular framework for opioid receptor modulators","volume":"138","author":"Kruegel","year":"2016","journal-title":"Journal of the American Chemical Society"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0520","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.neuropharm.2017.08.026","article-title":"The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse","volume":"134","author":"Kruegel","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0525","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1021\/acscentsci.9b00141","article-title":"7-Hydroxymitragynine is an active metabolite of mitragynine and a key mediator of its analgesic effects","volume":"5","author":"Kruegel","year":"2019","journal-title":"ACS Central Science"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0530","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev.pharmtox.38.1.289","article-title":"The role of receptor kinases and arrestins in G protein\u2013coupled receptor regulation","volume":"38","author":"Krupnick","year":"1998","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0535","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1016\/j.bja.2020.09.021","article-title":"Approval of oliceridine (TRV130) for intravenous use in moderate to severe pain in adults","volume":"125","author":"Lambert","year":"2020","journal-title":"British Journal of Anaesthesia"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0540","series-title":"Fowler\u2019s zoo and wild animal medicine","first-page":"589","article-title":"Thiafentanil oxalate (A3080) in nondomestic ungulate species","author":"Lance","year":"2012"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0545","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/j.cell.2020.11.014","article-title":"How GPCR phosphorylation patterns orchestrate arrestin-mediated signaling","volume":"183","author":"Latorraca","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0550","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1126\/science.1109237","article-title":"Transduction of receptor signals by \u03b2-arrestins","volume":"308","author":"Lefkowitz","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0555","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1016-8478(23)13700-9","article-title":"Molecular mechanisms mediating inhibition of G protein-coupled inwardly-rectifying K+ channels","volume":"15","author":"Lei","year":"2003","journal-title":"Molecules and Cells"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0560","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.brainres.2005.12.066","article-title":"Comparison of the in vitro efficacy of \u03bc, \u03b4, \u03ba and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes","volume":"1073\u20131074","author":"Lester","year":"2006","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0565","doi-asserted-by":"crossref","first-page":"20015","DOI":"10.1039\/C7RA01346A","article-title":"Synthesis and biological evaluation of fentanyl acrylic derivatives","volume":"7","author":"Li","year":"2017","journal-title":"RSC Advances"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0570","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ejmech.2019.01.063","article-title":"The in vivo antinociceptive and \u03bc-opioid receptor activating effects of the combination of N-phenyl-2\u2032,4\u2032-dimethyl-4,5\u2032-bi-1,3-thiazol-2-amines and naloxone","volume":"167","author":"Lin","year":"2019","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0575","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1242\/jcs.115.3.455","article-title":"The role of \u03b2-arrestins in the termination and transduction of G-protein-coupled receptor signals","volume":"115","author":"Luttrell","year":"2002","journal-title":"Journal of Cell Science"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0580","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1242\/jcs.03338","article-title":"\u03b2-arrestin signaling and regulation of transcription","volume":"120","author":"Ma","year":"2007","journal-title":"Journal of Cell Science"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0585","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature19112","article-title":"Structure-based discovery of opioid analgesics with reduced side effects","volume":"537","author":"Manglik","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0590","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1124\/mol.110.066613","article-title":"\u03bc-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization","volume":"78","author":"McPherson","year":"2010","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0595","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1007\/s00204-016-1812-x","article-title":"New psychoactive substances: an overview on recent publications on their toxicodynamics and toxicokinetics","volume":"90","author":"Meyer","year":"2016","journal-title":"Archives of Toxicology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0600","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aas9609","article-title":"Multisite phosphorylation is required for sustained interaction with GRKs and arrestins during rapid \u03bc-opioid receptor desensitization","volume":"11","author":"Miess","year":"2018","journal-title":"Science Signaling"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0605","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0168-0102(95)00933-K","article-title":"Molecular biology of the opioid receptors: structures, functions and distributions","volume":"23","author":"Minami","year":"1995","journal-title":"Neuroscience Research"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0610","doi-asserted-by":"crossref","first-page":"17395","DOI":"10.1038\/s41598-020-73674-0","article-title":"Dissecting the roles of GRK2 and GRK3 in \u03bc-opioid receptor internalization and \u03b2-arrestin2 recruitment using CRISPR\/Cas9-edited HEK293 cells","volume":"10","author":"M\u00f8ller","year":"2020","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0615","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1744806917740030","article-title":"Usefulness for the combination of G protein- and \u03b2-arrestin-biased ligands of \u03bc-opioid receptors: Prevention of antinociceptive tolerance","volume":"13","author":"Mori","year":"2017","journal-title":"Molecular Pain"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0620","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/j.febslet.2015.07.025","article-title":"Phosphoproteomic analysis of the mouse brain mu-opioid (MOP) receptor","volume":"589","author":"Moul\u00e9dous","year":"2015","journal-title":"FEBS Letters"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0625","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s10571-020-00973-5","article-title":"Mu opioids induce biased signaling at the full-length seven transmembrane C-terminal splice variants of the mu opioid receptor gene, oprm1","volume":"41","author":"Narayan","year":"2020","journal-title":"Cellular and Molecular Neurobiology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0630","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1177\/1087057111406548","article-title":"Understanding the effect of different assay formats on agonist parameters: A study Using the \u03bc-opioid receptor","volume":"16","author":"Nickolls","year":"2011","journal-title":"Journal of Biomolecular Screening"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0635","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/emmm.201201980","article-title":"The K + channel GIRK2 is both necessary and sufficient for peripheral opioid-mediated analgesia","volume":"5","author":"Nockemann","year":"2013","journal-title":"EMBO Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0640","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.neuropharm.2013.06.010","article-title":"Remifentanil produces cross-desensitization and tolerance with morphine on the mu-opioid receptor","volume":"73","author":"Nowoczyn","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0645","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1021\/acs.jmedchem.9b01465","article-title":"Investigation of the adrenergic and opioid binding affinities, metabolic stability, plasma protein binding properties, and functional effects of selected indole-based kratom alkaloids","volume":"63","author":"Obeng","year":"2020","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0650","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1124\/jpet.120.000189","article-title":"Pharmacological comparison of mitragynine and 7-hydroxymitragynine: in vitro affinity and efficacy for \u03bc -opioid receptor and opioid-like behavioral effects in rats","volume":"376","author":"Obeng","year":"2021","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0655","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/s41589-020-0535-8","article-title":"TRUPATH, an open-source biosensor platform for interrogating the GPCR transducerome","volume":"16","author":"Olsen","year":"2020","journal-title":"Nature Chemical Biology"},{"key":"10.1016\/j.pharmthera.2022.108161_bib961","doi-asserted-by":"crossref","DOI":"10.1002\/dta.3238","article-title":"Investigation of the \u03bc and \u03ba\u2010opioid receptor activation by eight new synthetic opioids using the [ 35 S]\u2010GTP\u03b3S assay: U\u201047700, isopropyl U\u201047700, U\u201049900, U\u201047931E, N \u2010methyl U\u201047931E, U\u201051754, U\u201048520 and U\u201048800","author":"Otte","year":"2022","journal-title":"Drug Testing and Analysis"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0660","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1016\/0024-3205(87)90431-0","article-title":"Morphine-6-glucuronide, a potent mu agonist","volume":"41","author":"Pasternak","year":"1987","journal-title":"Life Sciences"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0665","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1124\/pr.112.007138","article-title":"Mu opioids and their receptors: evolution of a concept","volume":"65","author":"Pasternak","year":"2013","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0670","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/bja\/aen094","article-title":"Opioids and the control of respiration","volume":"100","author":"Pattinson","year":"2008","journal-title":"British Journal of Anaesthesia"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107718","article-title":"Biased agonism of clinically approved \u03bc-opioid receptor agonists and TRV130 is not controlled by binding and signaling kinetics","volume":"166","author":"Pedersen","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0680","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1007\/s00204-020-02836-w","article-title":"In vitro structure\u2013activity relationship determination of 30 psychedelic new psychoactive substances by means of \u03b2-arrestin 2 recruitment to the serotonin 2A receptor","volume":"94","author":"Pottie","year":"2020","journal-title":"Archives of Toxicology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0685","article-title":"Identification of psychedelic new psychoactive substances (NPS) showing biased agonism at the 5-HT2AR through simultaneous use of \u03b2-arrestin 2 and miniG\u03b1q bioassays","volume":"114251","author":"Pottie","year":"2020","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0690","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1021\/acsptsci.0c00189","article-title":"Serotonin 2A receptor (5-HT 2A R) activation by 25H-NBOMe positional isomers: in vitro functional evaluation and molecular docking","volume":"4","author":"Pottie","year":"2021","journal-title":"ACS Pharmacology & Translational Science"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0695","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/0169-328X(94)00264-F","article-title":"Properties of a \u03ba-opioid receptor expressed in CHO cells: interaction with multiple G-proteins is not specific for any individual G\u03b1 subunit and is similar to that of other opioid receptors","volume":"29","author":"Prather","year":"1995","journal-title":"Molecular Brain Research"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0700","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/ADM.0000000000000324","article-title":"Misuse of novel synthetic opioids: a deadly new trend","volume":"11","author":"Prekupec","year":"2017","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0705","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1021\/acschemneuro.8b00363","article-title":"Synthesis and boological evaluation of fentanyl analogues modified at phenyl groups with alkyls","volume":"10","author":"Qin","year":"2019","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0710","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1124\/jpet.105.087254","article-title":"Morphine side effects in \u03b2-arrestin 2 knockout mice","volume":"314","author":"Raehal","year":"2005","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0715","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1124\/mol.111.072801","article-title":"Quantifying ligand bias at seven-transmembrane receptors","volume":"80","author":"Rajagopal","year":"2011","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0720","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.tem.2006.03.008","article-title":"GRKs and \u03b2-arrestins: roles in receptor silencing, trafficking and signaling","volume":"17","author":"Reiter","year":"2006","journal-title":"Trends in Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0725","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1124\/mol.112.078659","article-title":"Endomorphin-2: a biased agonist at the \u03bc-opioid receptor","volume":"82","author":"Rivero","year":"2012","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0730","series-title":"Veterinary pharmacology and therapeutics","year":"2017"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0735","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.cell.2017.10.035","article-title":"Bias factor and therapeutic window correlate to predict safer opioid analgesics","volume":"171","author":"Schmid","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0740","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ejphar.2015.05.012","article-title":"Opioid receptors: structural and mechanistic insights into pharmacology and signaling","volume":"763","author":"Shang","year":"2015","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0745","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11419-018-0454-5","article-title":"The search for the \u201cnext\u201d euphoric non-fentanil novel synthetic opioids on the illicit drugs market: current status and horizon scanning","volume":"37","author":"Sharma","year":"2019","journal-title":"Forensic Toxicology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0750","article-title":"Asymmetric syntheses of (+)- and (\u2212)-collybolide enable reevaluation of kappa-opioid receptor agonism (preprint)","author":"Shevick","year":"2022","journal-title":"Chemistry."},{"key":"10.1016\/j.pharmthera.2022.108161_bb0755","doi-asserted-by":"crossref","first-page":"eaay1833","DOI":"10.1126\/science.aay1833","article-title":"Noncanonical scaffolding of G\u03b1i and \u03b2-arrestin by G protein\u2013coupled receptors","volume":"371","author":"Smith","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0760","article-title":"Low intrinsic efficacy alone cannot explain the improved side effect profiles of new opioid agonists","author":"Stahl","year":"2021","journal-title":"Biochemistry."},{"key":"10.1016\/j.pharmthera.2022.108161_bb0765","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.3390\/ijms15011481","article-title":"Dopamine D4 receptor counteracts morphine-induced changes in \u03bc opioid receptor signaling in the striosomes of the rat caudate putamen","volume":"15","author":"Su\u00e1rez-Boomgaard","year":"2014","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0770","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/BF00427694","article-title":"Species differences in the relative analgesic potencies of some classical opiates and opioid peptides","volume":"82","author":"Sz\u00e9kely","year":"1984","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0775","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41392-021-00548-w","article-title":"The natural analgesic conolidine targets the newly identified opioid scavenger ACKR3\/CXCR7","volume":"6","author":"Szpakowska","year":"2021","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0780","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/20961790.2019.1588933","article-title":"Novel synthetic opioids \u2013 toxicological aspects and analysis","volume":"4","author":"Tabarra","year":"2019","journal-title":"Forensic Sciences Research"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0785","first-page":"916","article-title":"Chemistry and pharmacology of analgesic indole alkaloids from the Rubiaceous plant","volume":"52","author":"Takayama","year":"2004","journal-title":"Mitragyna Speciosa"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0790","doi-asserted-by":"crossref","first-page":"19158","DOI":"10.1038\/s41598-020-76119-w","article-title":"Chemical composition and biological effects of kratom (Mitragyna speciosa): in vitro studies with implications for efficacy and drug interactions","volume":"10","author":"Todd","year":"2020","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0795","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1021\/acschemneuro.1c00037","article-title":"DARK classics in chemical neuroscience: Etonitazene and related benzimidazoles","volume":"12","author":"Ujv\u00e1ry","year":"2021","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0800","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/S0022-3565(24)39167-0","article-title":"Interaction of p-fluorofentanyl on cloned human opioid receptors and exploration of the role of Trp-318 and His-319 in \u03bc-opioid receptor selectivity","volume":"294","author":"Ulens","year":"2000","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0805","series-title":"UNODC Early Warning Advisory on New Psychoactive Substances","author":"UNODC","year":"2020"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0810","series-title":"Current NPS threats","volume":"Vol. III","author":"UNODC","year":"2020"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0815","series-title":"World Drug Report 2020","volume":"Vol. E.20.XI.6","author":"UNODC","year":"2020"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0820","series-title":"The growing complexity of the opioid crisis. Global SMART Update","volume":"Vol. 24","author":"UNODC","year":"2020"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0825","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.56519","article-title":"Controlling opioid receptor functional selectivity by targeting distinct subpockets of the orthosteric site","volume":"10","author":"Uprety","year":"2021","journal-title":"eLife"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0830","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1021\/acschemneuro.1c00064","article-title":"Synthesis, chemical characterization, and \u00b5-opioid receptor activity assessment of the emerging group of \"nitazene\" 2-benzylbenzimidazole synthetic opioids","volume":"12","author":"Vandeputte","year":"2021","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0835","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1007\/s00204-020-02855-7","article-title":"In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances","volume":"94","author":"Vandeputte","year":"2020","journal-title":"Archives of Toxicology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0840","first-page":"1","article-title":"Phenethyl-4-ANPP: a marginally active byproduct suggesting a switch in illicit fentanyl synthesis routes","author":"Vandeputte","year":"2021","journal-title":"Journal of Analytical Toxicology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0845","article-title":"The rise and fall of isotonitazene and brorphine: two recent stars in the synthetic opioid firmament","volume":"bkab082","author":"Vandeputte","year":"2021","journal-title":"Journal of Analytical Toxicology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0850","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00204-021-03207-9","article-title":"Characterization of recent non-fentanyl synthetic opioids via three different in vitro \u03bc-opioid receptor activation assays","volume":"96","author":"Vandeputte","year":"2022","journal-title":"Archives of Toxicology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0855","doi-asserted-by":"crossref","first-page":"8381","DOI":"10.1021\/acs.jmedchem.6b00748","article-title":"Mitragynine\/Corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism, which do not recruit \u03b2-arrestin-2","volume":"59","author":"V\u00e1radi","year":"2016","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0860","article-title":"Respiratory depressant effects of fentanyl analogs are opioid receptor-mediated","volume":"114805","author":"Varshneya","year":"2021","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0865","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3390\/biom9080368","article-title":"Heterodimerization of mu opioid receptor protomer with dopamine D2 receptor modulates agonist-induced internalization of mu opioid receptor","volume":"9","author":"Vasudevan","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0870","doi-asserted-by":"crossref","first-page":"8015","DOI":"10.1007\/s00216-020-02945-6","article-title":"A novel nanobody-based bio-assay using functional complementation of a split nanoluciferase to monitor Mu-opioid receptor activation","volume":"412","author":"Vasudevan","year":"2020","journal-title":"Analytical and Bioanalytical Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0875","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113910","article-title":"Assessment of structure-activity relationships and biased agonism at the Mu opioid receptor of novel synthetic opioids using a novel, stable bio-assay platform","volume":"177","author":"Vasudevan","year":"2020","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0880","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2174\/1874467210666170704110146","article-title":"Opioids in the frame of new psychoactive substances network: a complex pharmacological and toxicological issue","volume":"11","author":"Ventura","year":"2018","journal-title":"Current Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0885","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1093\/jat\/bkaa094","article-title":"First report on brorphine: the next opioid on the deadly new psychoactive substances\u2019 horizon?","volume":"44","author":"Verougstraete","year":"2020","journal-title":"Journal of Analytical Toxicology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0890","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/15563650.2021.1879111","article-title":"Death associated with brorphine, an emerging novel synthetic opioid","volume":"59","author":"Vohra","year":"2021","journal-title":"Clinical Toxicology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0895","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.yrtph.2010.12.007","article-title":"Uniform assessment and ranking of opioid \u03bc receptor binding constants for selected opioid drugs","volume":"59","author":"Volpe","year":"2011","journal-title":"Regulatory Toxicology and Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0900","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1007394","article-title":"Molecular mechanisms of fentanyl mediated \u03b2-arrestin biased signaling","volume":"16","author":"de Waal","year":"2020","journal-title":"PLoS Computational Biology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0905","first-page":"953","article-title":"Opioid receptors. Annual Reviews of","volume":"73","author":"Waldhoer","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0910","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.bcp.2007.02.001","article-title":"Effects of chronic opioid exposure on guinea pig mu opioid receptor in Chinese hamster ovary cells: comparison with human and rat receptor","volume":"73","author":"Wallisch","year":"2007","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0915","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/0963689718811060","article-title":"Historical review: opiate addiction and opioid receptors","volume":"28","author":"Wang","year":"2019","journal-title":"Cell Transplantation"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0920","doi-asserted-by":"crossref","first-page":"9914","DOI":"10.1073\/pnas.95.17.9914","article-title":"Morphine-activated opioid receptors elude desensitization by \u03b2-arrestin","volume":"95","author":"Whistler","year":"1998","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0925","series-title":"Pharmacological reviews","first-page":"223","article-title":"Regulation of \u03bc -opioid receptors: Desensitization, phosphorylation, internalization, and tolerance","volume":"65","author":"Williams","year":"2013"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0930","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.3390\/ijms20122958","article-title":"Luminescence-and fluorescence-based complementation assays to screen for GPCR oligomerization: current state of the art","volume":"20","author":"Wouters","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0935","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.08.025","article-title":"Insights into biased signaling at cannabinoid receptors: synthetic cannabinoid receptor agonists","volume":"169","author":"Wouters","year":"2019","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0940","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1021\/acsptsci.9b00069","article-title":"Assessment of biased agonism among distinct synthetic cannabinoid receptor agonist scaffolds","volume":"3","author":"Wouters","year":"2020","journal-title":"ACS Pharmacology & Translational Science"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0945","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0022-3565(24)35398-4","article-title":"Ligand-induced changes in surface \u03bc-opioid receptor number: relationship to G protein activation?","volume":"292","author":"Zaki","year":"2000","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0950","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3389\/fpsyt.2017.00110","article-title":"An expanding world of novel psychoactive substances: opioids","volume":"8","author":"Zawilska","year":"2017","journal-title":"Frontiers in Psychiatry"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0955","doi-asserted-by":"crossref","first-page":"7157","DOI":"10.1073\/pnas.95.12.7157","article-title":"Role for G protein-coupled receptor kinase in agonist-specific regulation of -opioid receptor responsiveness","volume":"95","author":"Zhang","year":"1998","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2022.108161_bb0960","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cell.2017.07.002","article-title":"Identification of phosphorylation codes for arrestin recruitment by G protein-coupled receptors","volume":"170","author":"Zhou","year":"2017","journal-title":"Cell"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725822000559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725822000559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:23:36Z","timestamp":1759011816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725822000559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":193,"alternative-id":["S0163725822000559"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108161","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro functional assays as a tool to study new synthetic opioids at the \u03bc-opioid receptor: Potential, pitfalls and progress","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108161","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108161"}}